June 28, 2013

As part of the agreement signed by all the ASEAN countries, the Philippines will begin to only accept dossiers submitted under the ACTD (ASEAN Common Technical Dossier) Guidelines. While submitting guidelines under ACTD has been allowed since 2007, most companies opted to register under the local Philippine guidelines as the number of examiners for the ACTD were few in number, resulting in delayed registration.

This step to only allow ACTD is in line with the other proposed changes in the Philippine FDA, including the recent decision to increase FDA fees in some areas by more than 1,000 %.  The ACTD was scheduled along with the increase of fees to be implemented by July 1, 2013, however, with the recent resignation of Dr. Go the director of the FDA, the implementation of the ACTD and the fees has been delayed.

No final date has yet to be released by the FDA regarding the exact date of implementation although DOH Secretary Ona will be holding a conference next week with industry stakeholders to discuss the implementation.

Triple i Consulting is the only ISO:9001 2008 registered regulatory affairs specialist in the Philippines. Assisting both large mutli-national firms as well as small generic drug companies with the registration of food, drug, medical device , and clinical trials . For more information please feel free to contact us .


Contact us

Contact us below by filling out the form or just email us a message using the email

First Name (required)

Last Name (required)

Your Email (required)

Phone (Enter Your Phone Number if You'd Like Us to Call You)

Your Message

Enter the Captcha

友情链: IM体育数据最新版分析|预测推荐|IM体育现场视频比赛 | 2022im体育网上赛事_预测滚球_2022im体育结果回放时间 | im体育电脑版_分析官方赛事_im体育开户买球 | 2022im体育直播赛程官网|im体育的虚拟比赛技巧|2022im体育app赛事在线 | im体育电竞app|IM体育半决赛最新直播|IM体育正规版 | IM·体育平台官网_期胜负彩推荐_IM·体育盘口手机版 | 2022im体育软件注册可靠|v10.8 IOS版|2022im体育免费在线 |